STAT+: A Sellas immunotherapy study, long delayed, will end in failure
Why Sellas' experimental immunotherapy study is a blowup waiting to happen.
16 days ago STAT News
Search
148 stories found
STAT+: A biotech hedge fund births a new immunology company
Why a biotech hedge fund decided to build from the ground up a new company to develop a better, long-acting antibody treatment for atopic dermatitis.
16 days ago STAT News
Opinion: What happened to oppositional defiant disorder?
Over the past 25 years, there’s been a dramatic change in how we understand children who don’t “listen,” writes behavioral pediatrician Lawrence Diller.
16 days ago STAT News
STAT+: The FDA’s rebuilding effort is running into a new challenge
The FDA's plan to hire thousands of new workers is being slowed by an overwhelmed HR center.
16 days ago STAT News
New lawsuit argues NIH violated First Amendment rights of grant applicants
The lawsuit seeks to halt the process of searching grant applications for specific terms to determine if they should be rejected.
16 days ago STAT News
STAT+: GOP aims to change Medicare adviser’s math so it’s more favorable to health insurers
The GOP bill directs MedPAC to study the topic of overpayments to Medicare Advantage plans in a manner that’s more favorable to insurers.
16 days ago STAT News
STAT+: Senators highlight the power Chris Klomp wields at confirmation hearings
Chris Klomp has already played a major role in the Trump administration and its Make America Healthy Again agenda.
16 days ago STAT News
WHO expresses cautious optimism about bid to control Ebola outbreak in DRC
There is reason to be cautiously optimistic about the trajectory of the current Ebola outbreak in the Democratic Republic of the Congo, the WHO says.
17 days ago STAT News